PARP inhibitors blaze a trail in difficult-to-treat cancers.
Kling
Jim
J
D000970:Antineoplastic Agents / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use*; D004345:Drug Industry / Q000191:economics / Q000639:trends; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008958:Models, Molecular; D009369:Neoplasms / Q000188:drug therapy*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000737:chemistry
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases